Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: Hyrulean King who wrote (1815)	6/25/1998 6:28:00 PM
From: george willse	Read Replies (3) \| Respond to of 5402

Chief - Thanks! Has a time line been established? The way I see it, if it is successfully used in other countries we receive 3-4 benefits, as long as SGNC retains control of the product: 1. Revenues that add to the bottom line ( although $300/pint may be high for 2nd/3rd world counties) 2. #1 results in a viable eps value 3. Success will draw in backers or buyers, either of which will help speed the introduction into the states 4. The FDA has a policy of speeding up approval if certain criteria are met. SGNC could qualify under this circumstance and get to the US market quickly. Cheers, George PS. All this presumes that an immediate buy out is not currently in the works. One other question, what is the reporting status of SGNC?